Introduction
The endogenous opioid and cannabinoid systems are central in mediating and modulating neurophysiological responses to several drugs of abuse. Central cannabinoid receptor or cannabinoid receptor type 1 (CB1, CNR1) is found predominantly in the brain and is expressed in multiple regions, including those important for drug reward. [1] [2] [3] A second type of cannabinoid receptors, CNR2, has been found in immune cells as well as in the spleen 4 and in brain-stem neurons.
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-Tetrahydrocannabinol, the principal psychoactive component of marijuana, is an agonist of both CNR1 and CNR2 (for review see Howlett et al. 6 ). N-arachidonoyl ethanolamine (anandamide) 7 and 2-arachydonoylglycerol 8 are endogenous ligands of the CNR1.
Fatty acid amide hydrolase (FAAH) is important in the inactivation of some endogenous ligands of CNR1, including anandamide and 2-arachydonoylglycerol (for review see Deutsch et al. 9 and McKinney and Cravatt 10 ). Endogenous brain levels of anandamide and other amides of fatty acids are increased up to 15-fold in FAAH knockout mice. 11 The missense substitution 385C4A in FAAH converts a conserved proline residue to threonine (129P4T) that results in increased sensitivity of this enzyme to proteolytic degradation 12 and reduced FAAH expression and activity as measured in lymphocytes from human subjects. 13 These abnormalities in the properties of the 385A variant of FAAH are considered to be a potential link between functional abnormalities in the endogenous cannabinoid system and drug abuse and dependence, and have been reported to be an important risk factor for problem drug use and street drug use. 12 Precipitation of an abstinence syndrome in cannabinoiddependent rats by blockade of opioid receptors by naloxone 14 indicates cross-interaction between cannabinoid and opioid systems in neuronal pathways. In animal models, acute administration of SR141716A (Rimonabant hydrochloride), a selective central CNR1 antagonist, blocked heroin selfadministration in rats, as well as morphine-induced place preference and morphine self-administration in mice. 15 A more recent study showed that motivational and reinforcing effects of heroin are mediated by activation of CB1 receptors. 16 In CNR1 knockout mice, morphine did not modify dopamine release in the nucleus accumbens in areas of the brain involved in the reinforcing effects of morphine. 17 Mice lacking CNR1 failed to self-administer morphine, but did self-administer nicotine, cocaine and amphetamines. 18 In humans, several polymorphic sites including the triplet polymorphism 18087-18131(TAA) 8À17 have been identified in the CNR1 gene [19] [20] [21] , which is located on chromosome 6 at 6q14-q15. 22 Earlier studies of a possible association of 18087-18131(TAA) 8À17 with neuropsychiatric diseases were inconclusive. No association of this variant with mood disorders 23 or with schizophrenia 24 was found in a Taiwanese population, although in a Japanese cohort 18087-18131(TAA) 8À17 was shown to confer a susceptibility for schizophrenia, especially of the hebephrenic type. 25 In Germans, no association with schizophrenia of this polymorphism, rs6454674, or rs1049353 was found. 26 This repeat polymorphism has been reported to be associated with diverse intravenous injection in non-Hispanic Caucasians, 27 but not with heroin abuse in Han Chinese. 28 For this study, we selected high-frequency single nucleotide polymorphisms (SNPs) from the promoter regions of the CNR1 gene that were previously shown to be in association with polysubstance abuse. 21 Another SNP chosen for this study, 1359G4A, is located in the coding region of the gene.
In the CNR1 gene, we found a significant association of long repeats (X14) of 18087-18131(TAA) 8À17 with heroin addiction in Caucasians and an association of long repeats with heroin addiction across three ethnicities combined. Also in Caucasians only, we found associations of allele 1359A and genotype 1359AA with protection from heroin addiction.
Materials and methods
Study subjects: recruitment and diagnostic procedures For this study, African American, Caucasian, Hispanic and Asian unrelated subjects were recruited between 7 February 1995 and 31 May 2005 in New York City. The Rockefeller University Hospital Institutional Review Board-approved informed consent for genetic studies was obtained from all subjects. Subjects provided self-reported ethnicity.
Individuals were included in the former heroin-addicted group if they met Federal regulations for admission to methadone maintenance treatment: more than 1 year of daily multiple dose self-administration of heroin or other illicitly used opiates; 29 these criteria are significantly more stringent than those of a diagnosis of heroin addiction by Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria 30 and are quantitatively defined subphenotype of opiate addiction. Subjects with prior or continuing codependence on other illicit drugs or alcohol were not excluded as long as opiate dependence was the primary diagnosis.
To increase the precision and provide more detailed characterization of the subjects involved in our research, we characterized a subgroup of our subjects, including both former heroin-addicted and control subjects recruited between 26 June 2000 and 31 May 2005, by the Kreek-McHugh-Schluger-Kellogg scale, which quantifies frequency, mode, amount and duration of self-exposure to opiates, cocaine, alcohol and tobacco. 31 Exclusion criteria for the control subjects entering the study were as previously published. 32 Control subjects had no history of any extended period of drug or alcohol abuse or dependence. Subjects who used cannabis 412 days during the previous 30 days were excluded from the control group. Use of nicotine or caffeine was not an exclusion criterion for this group. Subjects with each parent from a different ethnic group (mixed ethnicity) were excluded from the study. Asians were excluded from the association analysis due to low numbers.
CNR1
Genotyping DNA was extracted from blood specimens using a salting-out procedure followed by ethanol precipitation and stored at À80 1C until further use. In a search for novel polymorphisms, PCR amplification of the coding region of the human CNR1 gene in a subgroup of 205 DNA samples (including 30 former heroin-addicted and 48 control Caucasians, 51 former heroin-addicted and 16 control Hispanics, 18 former heroin-addicted and 23 control African Americans and 19 others) was performed using the following two primer pairs:
0 -CACCTTTTCATTGAGCATGG (Reverse 2), resulting in two overlapping fragments (909 and 910 nucleotides long, based on GenBank accession no. GBPRI 8217458). All oligonucleotide primers were from Midland Certified Reagent (Midland, TX, USA). Numbering of the polymorphism position is based upon the previously reported system that gives value þ 1 to the first nucleotide of the AUG initiation codon. PCR amplifications of 5-10 ng of DNA using Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA, USA) were performed on GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA) using step-down procedure: incubation at 95 1C for 5 min, 0 -fluorescein amidite (yielding PCR product with fluorescently labeled reverse strand). The amplification was performed using Platinum DNA polymerase in 5 ml volumes using a previously described step-down protocol (see above). Upon the completion of cycling, the reaction mixture was diluted with 20 ml of water and 0.5 of the resulting solution was used for fragment analysis on ABI 3700 and ABI 3730xl DNA analyzers (Applied Biosystems). The data were analyzed using GeneMapper 3.7 (Applied Biosystems) software by two independent researchers. The data provided by the ABI 3700 were consistent with the data provided by the ABI 3730xl with 3.14% error. The only repeated inconsistency between results provided by the two instruments was absence of the 9-triplet allele in any readings provided by the ABI 3730xl (1.24% error attributed to this discrepancy). All other inconsistencies were random. The results of fragment analysis were confirmed by regular sequencing of 38 samples, including 13 samples in which a 9-triplet allele was found using the ABI 3700.
Statistical analysis
Genotypic, multilocus genotype pattern (MLGP), and allelic association analyses were carried out between cases and controls, separately for each ethnicity. Likelihood ratio w 2 -tests 33, 34 were applied for significance testing in the resulting 2 Â n contingency tables, where n is the number of alleles or genotypes. In this study, the likelihood ratio w 2 -test was used rather than the Pearson w 2 -test because it is less sensitive to small sample sizes.
Separate Bonferroni correction factors for multiple testing were applied for different tables presented in our study. In allelic and genotypic association tests (Table 1) , data were corrected for the number of SNPs studied. In allelic and genotypic association of microsatellite repeats (Table 2  and Supplementary Table S3 , respectively) the data were corrected for the number of individual alleles or genotypes analyzed in each ethnic group separately. In MLGP tests (Table 3 and Supplementary Table S4 ), data were corrected for the number of individual patterns analyzed in each ethnic group separately.
When analyzing association of genotype pairs of polymorphisms of the CNR1 and the FAAH genes with heroin addiction (Table 4) , permutation testing was performed to account for the fact that multiple tests were run. 35 This consisted of randomizing case-control status and rerunning the analysis for the six SNPs. From each of the 50 000 permutations, the maximum w 2 -value from the six tests was obtained. Then the original w 2 -value for each of the six SNPs was compared to this distribution of maximum w 2 -values. The number of randomized maximum w 2 -values greater than the original w 2 -value divided by the total number of permutation samples was taken as an estimate for the experiment-wise P-value.
For the microsatellite marker, in addition to testing for allele frequency differences between case and control individuals, we took the sum of the two allele lengths in an individual as that individual's genotype and used the resulting n 'genotypes' in a w 2 -analysis as outlined above. Also for the microsatellite marker, an unadjusted logistic regression analysis was conducted where treatment group status was the response and length of repeat was the explanatory variable. In this model, an exponential betaweight is equivalent to the odds increase in susceptibility attributable to each unit increase in length. Hardy-Weinberg equilibrium was tested in cases and controls for each marker with likelihood ratio w 2 , separately for each ethnicity. If any group of individuals deviated significantly from Hardy-Weinberg equilibrium, genotypes were scrutinized for errors and TaqMan results were reexamined. Plots of linkage disequilibrium were generated with control samples using the program Haploview 4.0 (Cambridge, MA, USA). 36 
Results
Demographic details of the study subjects are shown in Table 5 . In control individuals, overall allele frequencies were significantly different among the four ethnicities for each marker tested except À6274A4T (Supplementary Table  S1 ). In Supplementary Table S2 no significant deviations from Hardy-Weinberg equilibrium were found in controls, but in cases significant deviations were observed for 1359G4A in African Americans and for À22959C4T, À6215A4C and À5489A4G in Hispanics, which might be an indication of an association. Allelic tests showed significant association of minor 1359A located in the coding region of the CNR1 gene with protection from addiction in Caucasians (P ¼ 0.006, odds ratio (OR) ¼ 0.53, Table 1E) . At the genotype level, a significant association with disease, for example, vulnerability to develop heroin addiction, was found for 1359GG in Caucasians (P ¼ 0.034, Table 1E) . Similarly, at the genotype level a significant association with disease was found for À22959TT in Hispanics (P ¼ 0.018, Table 1A ). No association of polymorphism 385C4A in the FAAH gene with heroin addiction was found either in genotype or allele tests (Table 1F) .
When examining the allelic association of microsatellite repeats 18087-18131(TAA) 8À17 with vulnerability to development of heroin addiction (Table 2) , we grouped the repeats into two categories using a median split: short (13 and fewer) and long (14 and more). Performing this test for each type of allele separately, we found a significantly increased frequency of the 14-copy allele (long type) in the former heroin-addicted group of African Americans (association with development of addiction, P ¼ 0.0042), which was consistent with the observed decreased frequency of the 11-copy allele (short type) in the addicted group of Caucasians (association with protection from heroin addiction, P ¼ 0.0061). An increased frequency of long repeats in former heroin-addicted groups was found in Caucasians (P ¼ 0.0102) when all short types of alleles were tested vs all long types. Genotypic association of microsatellite repeats with heroin addiction is shown in Supplementary  Table S3 . Logistic regression performed for the microsatellite marker showed an association of the length of the repeat with the disease status in Caucasians for both alleles (P ¼ 0.0213, Table 2 ) and genotypes (P ¼ 0.0190, Supplementary Table S3 ).
To evaluate the joint effect of the long repeats of microsatellite 18087-18131(TAA) 8À17 in the CNR1 gene in the three (independent) ethnic groups, we combined the three 1Àd.f. w
2 -values into a single normal deviate, Z ¼ SOw 2 /O3, where the square root of w 2 is positive in each ethnicity as the direction of association is the same in each of them. The two-sided significance level associated with the resulting Z ¼ 3.322 is P ¼ 0.0009. With only six SNPs genotyped in this study, even though various tests have been carried out, this result is clearly highly significant.
In Caucasians, we analyzed w 2 -and P-values for all fifteen SNP pairs formed by all six polymorphisms tested in this study. The results are shown in Table 4A , where P-values were corrected for multiple testing by permutation testing. One pair of SNPs, 1359G4A and À6274T4A, shows a significant difference in the frequencies of genotype patterns between cases and controls (P ¼ 0.0244). The corresponding genotype patterns (nine patterns total) for this pair of SNPs are shown in Table 4B (the pattern AA-AA was not observed). One particular genotype pattern, TT-GG for 1359G4A and À6274T4A, predominantly contributes to the effect of genotype pair with an OR of 2.875, 95% confidence interval ¼ (1.44, 5.74), which represents the joint effect of these SNPs toward susceptibility to develop heroin addiction. This effect was not found in the AfricanAmerican and Hispanic ethnicities.
MLGPs were formed for the five SNPs of the CNR1 gene: À22959C4T, À6274T4A, À6215A4C, À5489A4G and 1359G4A (Table 3) . These patterns correspond to the splice variants A-D of CNR1 according to the study of Uhl's group. 21 Analysis of the corresponding pattern frequencies showed significant disease association for the pattern CC-TT-AA-AA-GG in Caucasians with P-value ¼ 0.0342 (OR ¼ 0.28, confidence interval ¼ (0.08, 0.94)). MLGPs with frequencies o5% in case and control individuals were combined into a 'rare' group. MLGP analysis for the splice variant E 21 of CNR1 is shown in Supplementary Table S4 . For this variant in Caucasians, a pattern TT-AA-AA-GG has been found to be associated with disease (P ¼ 0.003, OR ¼ 2.82), whereas the other pattern, TT-AA-AA-GA, was found to be associated with protection from the disease (P ¼ 0.008, OR ¼ 0.23). Analysis of haplotypes for the five SNPs À22959C4T, À6274T4A, À6215A4C, À5489A4G and 1359G4A of the CNR1 gene is shown in Supplementary  Table S5 . No association of any common haplotype with heroin addiction was found in any ethnic group studied.
Linkage disequilibrium plots were constructed for the five SNPs of control samples for each ethnicity separately. There was strong linkage disequilibrium between SNPs Figure S1) .
Using direct sequencing of the CNR1 gene in a subgroup of our subjects, we identified two novel synonymous SNPs in positions 366G4C (Leu-Leu) and 912C4T (His-His). The first polymorphism was found in one heterozygous sample and the second one in three heterozygous samples out of 205 total DNA samples sequenced.
Discussion
In this study, we found that results of an allelic association of 18087-18131(TAA) 8À17 in African-American and Caucasian study groups are consistent with each other: in separate tests for each type of the repeat number, a 14-copy repeat (long) was associated with vulnerability to develop heroin addiction in African Americans, whereas the 11-copy repeat (short) was associated with the protective effect from heroin addiction in Caucasians ( Table 2) . Association of long repeats with vulnerability to develop heroin addiction was consistent in Caucasians when all short repeats were grouped vs all long (Table 2) ; repeats longer than 13 were associated with vulnerability to develop heroin addiction with P ¼ 0.0009 over all ethnic groups combined. These findings are consistent with and extend the findings of Uhl's group. 21 Using data presented in that table, we found that the frequency of the short alleles is higher in the control group and the frequency of the long allele is higher in the abuser group of Caucasians. In another previous study, allele and genotype frequencies of 18087-18131(TAA) 8À17 were found to be significantly associated Association of a 14-triplet repeat with vulnerability to develop heroin addiction was found in African Americans, corrected for multiple testing P ¼ 0.0252 (correction factor is 6, the number of alleles studied in African Americans).
b Alleles with frequency o5% in each of the two treatment groups (controls, former heroin addicts) were combined into a 'rare' group. c When all three ethnic/cultural groups were considered together to determine whether the long repeats are associated with vulnerability to develop heroin addiction, specific calculations documented that the two-sided significance level associated with the resulting Z ¼ 3.322 is P ¼ 0.0009 (see Results). Association of an 11-triplet repeat with protection from the vulnerability to develop heroin addiction was found in Caucasians, corrected for multiple testing P ¼ 0.0305 (correction factor is 5, the number of alleles studied in Caucasians).
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In genotype tests of 18087-18131(TAA) 8À17 , we found increased frequency of the (TAA) 26 and (TAA) 25 in Caucasian and Hispanic control groups, respectively (Supplementary Table S3 ). In contrast, we found increased frequencies of the (TAA) 30 and the (TAA) 29 in former heroin-addicted Caucasians and in Hispanics, respectively.
We found that the patterns of previously reported frequencies for allelic distributions in different ethnic groups 21, 26, 37, 38 for the 18087-18131(TAA) 8À17 triplet are similar to those found in our study (Table 6 ), although the highest allele frequency in the control group in both African Americans and Caucasians is shifted by a 1-or 2-triplet repeat, which probably is the result of differences in the methodology.
The other polymorphism that was found in this study to be in association with a protective effect from heroin addiction in Caucasians is synonymous 1359G4A. Because this is the only high-frequency variant located in the coding region of CNR1, it has been previously tested for association with various neuropsychiatric conditions and substance abuse and dependence with inconclusive results. In Caucasians, it was associated with severe alcohol withdrawal. 39 No association of this polymorphism with a history of alcohol withdrawal-induced seizures was found. 40 In a study of schizophrenia in a French-Caucasian population, Leroy et al. 41 reported a lower representation of the 1359GG genotype in nonsubstance-abusing patients, compared to substance-abusing patients, suggesting an association between CNR1 variants and substance abuse in schizophrenia. In Germans, the 1359G4A was not found to be associated with schizophrenia. 26 Another study 42 found an association between cannabis use and schizophrenia in a population of Caucasians in the United Kingdom, but no association of 1359G4A with drug use. In a French cohort, there was no association of this polymorphism with schizophrenia, 43 although the frequency of the G allele was significantly higher among patients who were nonresponsive to antipsychotics. In German opioid addicts and age-and gendermatched controls, no association of the 1359G4A with intravenous drug addiction was found. 38 A study of CNR1 mRNAs by Uhl's group in Caucasian, African-American and Japanese populations revealed novel exonic sequences, splice variants and polymorphisms of CNR1.
21 Specific splice variants were expressed differentially in different brain regions: caudate, substantia nigra and amygdala express a large amount of the splice variant E of the CNR1 gene that contains exon 3, but not exons 1 and 2. 21 To study the influence of different splice variants on initiation of heroin addiction, we analyzed an association of patterns formed by five SNPs: À22959C4T, À6274T4A, Table S4 ). In Caucasians, for the four-SNP locus we found pattern TT-AA-AA-GG to be associated with disease (P ¼ 0.003, OR ¼ 2.82). In contrast, we found another pattern, TT-AA-AA-GA, to be associated with protection from the disease (P ¼ 0.008, OR ¼ 0.23). SNPs À22959C4T, À6274T4A and À5489A4G were reported to be associated with polysubstance abuse in European Americans; SNPs À6274T4A, À6215A4C and À5489A4G were found to be associated with polysubstance abuse in African Americans. 21 Another group 44 found no association of these SNPs (-6274T4A, À6215A4C and À5489A4G) with substance dependence diagnoses, including alcohol, cocaine and opioids in either European-American or African-American subjects. In our studies, we also found no association of these polymorphisms with vulnerability to develop heroin addiction in any ethnic group.
One study found an associations of À39884C4G (rs1884830), À17937T4G (rs6454674) and 4893T4C (rs806368) with drug dependence at the allele level and À39884C4G at the genotype level in European Americans. 45 Also in European Americans, associations of À39884C4G, À17937T4G, À6274T4A and 4893T4C SNPs with comorbid drug and alcohol dependence were found at the allele level. Interestingly, we found an association of the joint genotype that includes one of these SNPs, À6274T4A, with heroin addiction also in European Americans.
There were several studies of an association of missense substitution 385C4A in the FAAH gene (resulting in protein change 129P4T) with various diseases. In studies of a Japanese cohort, 46 no association of this polymorphism with either methamphetamine dependence or schizophrenia was found. SNP 385C4A has been reported as a risk factor for problem drug use and street drug use but not alcohol or tobacco use or dependence in Caucasians. 12, 47 In another study of a Caucasian cohort, 48 individuals with the 385AA genotype were found to be at reduced risk for cannabis dependence. In our studies, we did not find an association of 385C4A with heroin addiction. This might be a result of use of different phenotype criteria during subject classification.
Given the number of tests performed, some observed results may be due to type 1 error. A few values were no longer significant after correcting for multiple testing. A future study with a larger number of subjects would be important for confirmation of our findings. Taken together, our findings support the hypothesis of an involvement of ), the exact counting of the triplets is shifted by 1 or 2 repeats, which probably is the result of differences in the methodology. The reference allele of highest frequency (counted as 11 in our study) is highlighted in bold.
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